KAG-308, a newly-identified EP4-selective agonist shows efficacy for treating ulcerative colitis and can bring about lower risk of colorectal carcinogenesis by oral administration
本文档由 cvcbttop 分享于2016-06-24 10:07
KAG-308, a newly-identified EP4-selective agonist shows efficacy for treating ulcerative colitis and can bring about lower risk of colorectal carcinogenesis by oral administration
下载文档
收藏
打印
分享：
君，已阅读到文档的结尾了呢~~